A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression

Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persisten...

Full description

Saved in:
Bibliographic Details
Published innpj vaccines Vol. 9; no. 1; p. 22
Main Authors Zhao, Huajun, Shao, Xianyu, Yu, Yating, Huang, Lulu, Amor, Narh Philip, Guo, Kun, Weng, Changzhen, Zhao, Weijun, Yang, Ailu, Hu, Jiesen, Yang, Hongbao, Liu, Zhenguang, Han, Qiuju, Shi, Leilei, Sun, Shiyu, Zhang, Jian, Lin, Ang, Yang, Yong
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 03.02.2024
Nature Publishing Group
Nature Portfolio
Subjects
631/250/590/2293
631/326/590/2293
692/699/255/234/2513/1549
Antigens
Biomedical and Life Sciences
Biomedicine
Brief Communication
Cytotoxicity
Drug dosages
Hepatitis
Hepatitis B
Immunogenicity
Infectious Diseases
Liver
Lymphocytes
Medical Microbiology
mRNA vaccines
Pharmaceuticals
Pharmacy
Plasmids
Public Health
Vaccine
Vaccines
Virology
Online AccessGet full text

Cover

More Information
Summary:Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-024-00813-3